Abstract: Systems and methods for handling latent anomalies in field devices are described herein. When an anomaly is detected, the system can earmark the presence of the detected anomaly with a flag or other notification, and announce the existence of the anomaly to a user. In some embodiments, a self-test may be distributed to devices in the field that may be potentially affected by the latent anomaly so that those devices can monitor for the presence of the anomaly and take appropriate action if detected.

Abstract: Systems and methods for handling latent anomalies in field devices are described herein. When an anomaly is detected, the system can earmark the presence of the detected anomaly with a flag or other notification, and announce the existence of the anomaly to a user. In some embodiments, a self-test may be distributed to devices in the field that may be potentially affected by the latent anomaly so that those devices can monitor for the presence of the anomaly and take appropriate action if detected.

Abstract: Systems and methods for handling latent anomalies in field devices are described herein. When an anomaly is detected, the system can earmark the presence of the detected anomaly with a flag or other notification, and announce the existence of the anomaly to a user. In some embodiments, a self-test may be distributed to devices in the field that may be potentially affected by the latent anomaly so that those devices can monitor for the presence of the anomaly and take appropriate action if detected.

Abstract: Disclosed is a method for determining the turnover rate of biomolecules in a subject, which include administering to the subject, 2H2O in an amount sufficient to label biomolecules in the subject with 2H. Samples are collected from the subject at one or more time points and isotopomers are detected for the labeled biomolecules in the samples. The fractional abundance is determined for the isotopomers of the biomolecules in the samples and the biomolecule turnover rates of the one or more labeled biomolecules is determined based on the fractional abundance of the isotopomers. A computer-implemented method is also disclosed for determining the turnover rate of one or more biomolecules in subject. In certain other embodiments, a system for determining protein turnover rates in a subject is also provided. Also provided in certain embodiments is a computer program product for determining protein turnover rates in a subject.

Abstract: Systems and methods for handling latent anomalies in field devices are described herein. When an anomaly is detected, the system can earmark the presence of the detected anomaly with a flag or other notification, and announce the existence of the anomaly to a user. In some embodiments, a self-test may be distributed to devices in the field that may be potentially affected by the latent anomaly so that those devices can monitor for the presence of the anomaly and take appropriate action if detected.

Abstract: Disclosed is a method for determining the turnover rate of biomolecules in a subject, which include administering to the subject, 2H20 in an amount sufficient to label biomolecules in the subject with 2H. Samples are collected from the subject at one or more time points and isotopomers are detected for the labeled biomolecules in the samples. The fractional abundance is determined for the isotopomers of the biomolecules in the samples and the biomolecule turnover rates of the one or more labeled biomolecules is determined based on the fractional abundance of the isotopomers. A computer-implemented method is also disclosed for determining the turnover rate of one or more biomolecules in subject. In certain other embodiments, a system for determining protein turnover rates in a subject is also provided. Also provided in certain embodiments is a computer program product for determining protein turnover rates in a subject.

Abstract: Disclosed are compositions and methods for Disclosed are methods related to the use of Cdk2 inhibitors to reducing myocardial ischemic/reperfusion injury including but not limited to reduced infarct size. It is also disclosed that the same methods are equally appropriate for use in reducing injury following stroke including but not limited to (ischemic strokes (including strokes resulting from cerebral thrombosis, cerebral embolism, and atrial fibrillation), hemorrhagic strokes (including strokes resulting from aneurysm and arteriovenous malformation), and transient ischemic attack), reducing infarct size following pulmonary infarction, reducing renal ischemia injury, reducing ischemic/reperfusion injury occurring during cardiac surgery where a heart lung machine is used such as Coronary artery bypassing, and reducing ischemic/reperfusion injury occurring during the preservation of organs for transplant.